Rivastigmine Tartrate Capsule
Product Images NDC 33342-090

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 33342-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Rivastigmine Structure)

Chemical structure of rivastigmine tartrate, showing the molecular arrangement including aromatic ring, ester and amine groups, and the tartrate component.*

FDA Label Image

Figure-1 (Rivastigmine Figure 1)

A line graph illustrating mean change from baseline in ADAS-cog rating over weeks during treatment with rivastigmine tartrate capsules. The graph compares clinical improvement and decline for three groups: 6-12 mg, 1-4 mg, and placebo, with time points at 0, 12, 18, and 26 weeks. Error bars denote SEM.*

FDA Label Image

Figure-2 (Rivastigmine Figure 2)

A cumulative percentage plot showing patients' change from baseline with three treatment groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. Vertical lines indicate 7-point, 4-point improvements, and no change thresholds. An inset table summarizes percentage of patients achieving specified improvements in ADAS-cog scores across treatment groups.*

FDA Label Image

Figure-3 (Rivastigmine Figure 3)

A bar chart depicting the percentage of patients by CIBIC-Plus rating across three groups: Placebo, 1-4 mg, and 6-12 mg doses. Ratings range from Markedly Improved to Markedly Worse, showing most patients categorized as Unchanged, with smaller percentages in other categories.*

FDA Label Image

Figure-4 (Rivastigmine Figure 4)

A line graph depicting the mean change from baseline in ADAS-Cog ratings over 26 weeks of treatment. The graph compares clinical improvement and decline among three groups receiving 6-12 mg, 1-4 mg doses of a drug, and placebo. The 6-12 mg group shows noticeable clinical improvement around week 12, while the placebo and 1-4 mg groups trend towards clinical decline.*

FDA Label Image

Figure-5 (Rivastigmine Figure 5)

A cumulative percentage plot showing the change from baseline in ADAS-cog scores for three groups: 6-12 mg, 1-4 mg, and placebo. The x-axis represents change from baseline, with annotations for 7 points, 4 points, and no change; the y-axis shows cumulative percentage of patients. A table presents treatment group ADAS-cog change values at -7, -4, and 0 points.*

FDA Label Image

Figure-6 (Rivastigmine Figure 6)

A bar graph showing the percentage of patients categorized by CIBIC-Plus Rating for placebo, 1-4 mg, and 6-12 mg dosage groups of rivastigmine tartrate. The categories range from Markedly Improved to Markedly Worse, illustrating patient response distribution across treatment groups.*

FDA Label Image

Figure-7 (Rivastigmine Figure 7)

A line graph showing mean change from baseline ADAS-cog rating over 24 weeks during treatment with Rivastigmine versus placebo. The vertical axis represents mean change with error bars (SEM), ranging from clinical decline to clinical improvement. The horizontal axis shows time in weeks (0, 8, 16, 24). Rivastigmine shows increased clinical improvement over time compared to placebo.*

FDA Label Image

Figure-8 (Rivastigmine Figure 8)

Bar chart comparing the percentage of patients across ADCS-CGIC rating categories for Rivastigmine and Placebo groups. The ratings range from Markedly Improved to Markedly Worse, showing varying patient outcome distributions between the two groups.*

FDA Label Image

1.5mg-60s (Rivastigmine 1.5mg 60s)

Label for Rivastigmine Tartrate Capsules, USP 1.5 mg, containing 60 capsules. Manufactured by Macleods Pharmaceuticals Ltd and Macleods Pharma USA, Inc. The label includes dosage strength, storage instructions, and barcodes, with a specified area for additional labeling (43 x 20 mm). Indicated for oral use and prescription only.*

FDA Label Image

30s-1.5mg (Rivastigmine 30s 1.5mg)

Rivastigmine Tartrate Capsules USP 1.5 mg oral capsules label by Macleods Pharmaceuticals Limited. The label indicates a bottle containing 30 capsules (3 x 10 unit-dose). It includes manufacturer details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd., India, along with storage information and dosage reference statements. The strength 1.5 mg is highlighted in green on the label.*

FDA Label Image

100s-1.5mg (Rivastigmine 1.5 100)

Packaging label for Rivastigmine Tartrate Capsules, USP 1.5 mg by Macleods Pharmaceuticals Limited. The label displays the product strength (1.5 mg), dosage form (capsules), package quantity (100 capsules, 10 x 10 unit-dose capsules), and storage instructions. It includes the labeler name Macleods Pharma USA and manufacturing details from Macleods Pharmaceuticals Ltd, India.*

FDA Label Image

60s-3mg (Rivastigmine 60s 3mg)

The label for Rivastigmine Tartrate Capsules, USP 3 mg, displays the product name and strength prominently. It indicates a quantity of 60 capsules, for prescription use only, labeled by Macleods Pharma USA and manufactured by Macleods Pharmaceuticals Ltd. The label includes storage instructions and dosage details, alongside barcodes and the NDC 33342-090-09.*

FDA Label Image

30s-3mg (Rivastigmine 30s 3mg)

Packaging label for Rivastigmine Tartrate Capsules, USP, 3 mg strength. The label states there are 30 capsules (3 x 10 Unit-Dose Capsules) per pack. The product is labeled as Rx only, manufactured by Macleods Pharmaceuticals Ltd., Daman, India, and distributed by Macleods Pharma USA. Storage instructions and dosage reference to prescribing information are also included.*

FDA Label Image

100s-3mg (Rivastigmine 100s 3mg)

Rivastigmine Tartrate Capsules, USP 3 mg oral capsules packaging label from Macleods Pharmaceuticals Limited. The label indicates a bottle containing 100 capsules (10 x 10 unit-dose capsules). It includes manufacturer details, storage instructions, dosage strength, and note that the blister pack is not child resistant.*

FDA Label Image

60s-4.5mg (Rivastigmine 60s 4.5mg)

Rivastigmine Tartrate Capsules USP 4.5 mg label showing the drug name, strength, and dosage form. The label states the active ingredient as 4.5 mg rivastigmine equivalent per capsule, includes storage instructions, manufacturer details (Macleods Pharma USA and Macleods Pharmaceuticals Ltd. India), and package size of 60 capsules. The label indicates prescription use only.*

FDA Label Image

30s-4.5mg (Rivastigmine 30s 4.5mg)

Rivastigmine Tartrate Capsules, USP 4.5 mg by Macleods Pharmaceuticals Limited. The packaging shows a carton containing 30 capsules (3 x 10 Unit-Dose Capsules). It includes dosage strength, labeler information, storage instructions, and indicates it is for prescription use only.*

FDA Label Image

100s-4.5mg (Rivastigmine 100s 4.5mg)

Packaging label for Rivastigmine Tartrate Capsules, USP 4.5 mg by Macleods Pharmaceuticals Limited. The label indicates a package of 100 capsules (10 x 10 unit-dose capsules) intended for oral use. It includes storage instructions, dosage reference, and notes that the blister pack is not child resistant. Manufactured for Macleods Pharma USA, Inc.*

FDA Label Image

60s-6mg (Rivastigmine 60s 6mg)

Label for Rivastigmine Tartrate Capsules USP 6 mg by Macleods Pharmaceuticals Limited. The label includes the dosage form as capsules, the strength as 6 mg per capsule, and a package size of 60 capsules. It indicates this is a prescription drug with storage instructions and manufacturer details for Macleods Pharma USA and Macleods Pharmaceuticals Ltd. A barcode is present on the right side.*

FDA Label Image

30s-6mg (Rivastigmine 30s 6mg)

Rivastigmine Tartrate Capsules USP 6 mg packaging label from Macleods Pharmaceuticals Limited. The label shows a 30-count supply, packaged as 3 blister cards of 10 unit-dose capsules each. The label includes storage instructions and states the product is for prescription use only. Manufactured by Macleods Pharmaceuticals Ltd, India, and for Macleods Pharma USA, Inc.*

FDA Label Image

100s-6mg (Rivastigmine 100s 6mg)

Rivastigmine Tartrate Capsules, USP 6 mg oral capsules packaging label from Macleods Pharmaceuticals Limited. The label indicates 100 capsules (10 x 10 unit-dose capsules) and includes storage instructions, dosage reference, and manufacturer information for Macleods Pharma USA, Inc. The label also displays the NDC 33342-092-12 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.